LXEO vs NCLH · $147.7M cap vs P/E 16, rev $4.97B
Lexeo Therapeutics, Inc. Common Stock (LXEO) versus Norwegian Cruise Line Holdings Ltd (NCLH) — a side-by-side from cached financials, not a winner call.
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a biotechnology company listed on US.
Norwegian Cruise Line Holdings Ltd (NCLH) is a travel services company listed on NYSE.
LXEO does not have a complete income-statement cache yet.
Latest reported NCLH revenue for 2026-06-30 was $4.97B. Net income was $327.2M. NCLH currently screens at market cap $9.10B and trailing P/E 16.0.
LXEO currently screens at market cap $147.7M. NCLH currently screens at market cap $9.10B and trailing P/E 16.0.
Not investment advice. Open the LXEO and NCLH stock pages for the full models.
Not investment advice.